Summary NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”, the “Company”, “we”, “us” or “our”) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc., (NeuroRx), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, post-traumatic stress disorder (PTSD) and schizophrenia.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: small molecule (IV infusion formulation)
Target NMDA receptor
Status note Lead candidate; preservative-free formulation of ketamine for IV infusion. No phase or indication stated in excerpts.
KETAFREE
Stage not disclosed · ActiveModality: small molecule (generic formulation)
Target NMDA receptor
Status note Generic preservative-free formulation of ketamine. No phase or indication stated in excerpts.
NRX-101
Stage not disclosed · ActiveModality: small molecule (oral fixed-dose combination)
Status note Oral fixed-dose combination of D-cycloserine (DCS) and lurasidone. No phase or indication stated in excerpts.
NRX-200
Preclinical · ActiveModality: small molecule (subcutaneous formulation)
Status note pH-neutral form of ketamine suitable for subcutaneous administration.
Temelimab
Stage not disclosed · ActiveModality: monoclonal antibody
Target HERV-W envelope protein
Partnerships NIH (CRADA + shared patents); Fondation FundaMental of France (shared patents for schizophrenia). Held via GeNeuro, Inc. subsidiary (assets awarded by Swiss courts Jun 2026).
Indications
Multiple sclerosis (MS)(Stage not disclosed)
Type 1 diabetes(Stage not disclosed)
Long Covid(Stage not disclosed)
Status note Monoclonal antibody against HERV-W envelope protein (via GeNeuro, Inc.). Studied in MS, Type 1 diabetes, and Long Covid; preclinical work in schizophrenia. No phase stated in excerpts.
GNK-301
Preclinical · Active
Partnerships NIH (developed in partnership). Held via GeNeuro, Inc. subsidiary.
Indications
ALS(Preclinical)
Status note Preclinical asset developed in partnership with NIH (via GeNeuro, Inc.). Studied in ALS models and human brain cell culture.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.